Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
4.160
-0.050 (-1.19%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Evotec SE Revenue
In the year 2024, Evotec SE had annual revenue of 796.97M EUR with 1.99% growth. Evotec SE had revenue of 221.23M in the quarter ending December 31, 2024, with 9.89% growth.
Revenue (ttm)
796.97M EUR
Revenue Growth
+1.99%
P/S Ratio
1.81
Revenue / Employee
168,136 EUR
Employees
4,740
Market Cap
1.49B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 796.97M | 15.54M | 1.99% |
Dec 31, 2023 | 781.43M | 29.98M | 3.99% |
Dec 31, 2022 | 751.45M | 133.41M | 21.59% |
Dec 31, 2021 | 618.03M | 117.11M | 23.38% |
Dec 31, 2020 | 500.92M | 54.49M | 12.20% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
EVO News
- 3 days ago - Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb - Accesswire
- 10 days ago - Evotec SE (EVO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results - Accesswire
- 17 days ago - Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025 - Accesswire
- 7 weeks ago - Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb - Accesswire
- 2 months ago - Evotec Announces Change in Management Board - Accesswire
- 2 months ago - Advancing Data Centric AI in Healthcare and Life Sciences - Elucidata Onboards Former CEO of Evotec and Ex-McKinsey Senior Partner - Business Wire
- 3 months ago - Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases - Accesswire